Credit Valley EyeCare
Mississauga, Ontario, L5L 1W8, Canada
NCT Number: NCT01758237
To establish the correlation of the location of the Nd:YAG laser peripheral iridotomy to the post operative visual symptoms experienced by some patients. The investigators hypothesize that fully uncovered laser peripheral iridotomy will produce less significant dysphotopsia, due to avoidance of the prismatic effect produced by the tear film than those covered.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Mississauga, Ontario, L5L 1W8, Canada
Nd:YAG LPI is a frequently performed procedure for patients who have narrow angles at risk of acute angle closure glaucoma, pupillary-block conditions, chronic angle closure, and pigment dispersion syndrome. Most complications associated with the procedure are benign and include intraocular pressure (IOP) spike, transient uveitis, hyphema, corneal or lens damage and closure of the iridotomy. Visual disturbances have been also reported but only a few papers address this specific issue. The rate of these symptoms vary between 2.7% and 4%. It is believed that these symptoms are associated with the fact that light enters through the LPI and thus creating abnormal visual symptoms. Hence it has been suggested to carefully place the LPI so that the eyelid fully covers the LPI, therefore preventing light getting through. However, reports of patients with fully covered LPIs and visual disturbances have led to hypothesize the theory that even when fully covered by the eyelid, light can access through the LPI by a base-up prism created by the tear meniscus at the lid margin. Therefore, placement of the LPI, fully covered, partially covered or totally uncovered can potentially lead to equally significant symptoms. This study will attempt to address the issue of placement of the LPI in relationship with visual symptoms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
Other names: Nd:YAG Laser
After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
Other names: Nd:YAG LPI
Time frame: Baseline (Time =0),1 month
The change in presence of linear dysphotopsia from baseline (prior to intervention) to 1 month after the Nd:YAG laser intervention is performed.
Time frame: Baseline (Time = 0), 1 month
This includes Halo, Crescent, Ghost Images, Glare, Shadows. This records the change in the presence of these symptoms from baseline (prior to intervention) and 1 month after the Nd:YAG laser intervention.
Time frame: Procedure (Time = 0)
The pain experienced when the Nd:YAG procedure is performed. This is on a scale of 0-10 with 0 being no pain and 10 the most severe pain imaginable.
Time frame: Procedure (Time = 0)
The amount of laser power used on the Nd:YAG laser to perform the intervention.
Credit Valley EyeCare
Industry
Incidence of Visual Symptom Following Laser (Nd:YAG ) Peripheral Iridotomy (LPI) in Relation to Position of LPI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05236439
Eye Diseases, Glaucoma
Yerevan, Armenia
View Trial DetailsNCT07495449
Acute Ocular Hypertension Glaucoma, Eye Diseases
Shantou, Guangdong, China
View Trial DetailsNCT06120621
Eye Diseases, Glaucoma
Al Mansurah, Dakahlia Governorate, Egypt
View Trial DetailsNCT04602923
Eye Diseases, Glaucoma
Montreal, Quebec, Canada
View Trial Details